Divarasib Versus Adagrasib or Sotorasib in Pretreated KRAS G12C+Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

被引：0

作者：

Gadgeel, S. ^{[1
]}

Rahman, A. ^{[2
]}

Osaghae, U. ^{[3
]}

Fernando, T. M. ^{[3
]}

Lin, M. T. ^{[3
]}

Koli, K. ^{[3
]}

Meyenberg, C. ^{[4
]}

Mathisen, M. ^{[3
]}

Skoulidis, F. ^{[5
]}

机构：

[1] Henry Ford Hlth, Henry Ford Canc Inst, Detroit, MI USA

[2] F Hoffmann La Roche Ltd, Welwyn Garden City, Herts, England

[3] Genentech Inc, San Francisco, CA 94080 USA

[4] F Hoffmann La Roche Ltd, Basel, Switzerland

[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P3.12D.07

引用

页码：S349 / S349

页数：1

共 50 条

[1] MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) IN PREVIOUSLY TREATED KRAS G12C-MUTATED ADVANCED/METASTATIC NON-SMALL CELL LUNG CANCER (A/MNSCLC): ADAGRASIB VERSUS SOTORASIB
Bouwmeester, W.
Laurie, M.
Korytowsky, B.
Grevinga, M.
Qian, C.
Berardi, A.
Gao, S.
Stenehjem, D.
VALUE IN HEALTH, 2023, 26 (12) : S31 - S31
[2] Sotorasib vs Adagrasib: Matching-adjusted Indirect Comparison in Prior Treated KRAS G12C Advanced Non-Small Cell Lung Cancer
Chopra, D.
Waterhouse, D. M.
Sylvester, B.
Jamotte, A.
Stollenwerk, B.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S647 - S648
[3] COST PER RESPONDER ANALYSIS COMPARING ADAGRASIB AND SOTORASIB IN PATIENTS WITH KRAS G12C-MUTATED PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCER (NSCLC)
Berardi, A.
Laurie, M.
Theriou, C.
Orsini, I
Bouwmeester, W.
Gao, S.
Korytowsky, B.
VALUE IN HEALTH, 2023, 26 (12) : S119 - S120
[4] Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation
Zheng, Xinting
Luo, Jiamin
Liu, Wei
Ashby, Charles R., Jr.
Chen, Zhe-Sheng
Lin, Lizhu
DRUGS OF TODAY, 2022, 58 (04) : 175 - 185
[5] Krascendo-170 Lung: A phase Ib/II study of divarasib plus pembrolizumab ± platinum-based chemotherapy and pemetrexed in untreated KRAS G12C+advanced non-small cell lung cancer (NSCLC)
Skoulidis, Ferdinandos
Cuppens, Kristof
Sacher, Adrian G.
Velcheti, Vamsidhar
Lee, Dae Ho
Lin, Mark T.
Fernando, Tharu M.
Li, Shuai
Bradley, Denise
Crnkovic, Martina Zarak
Mathisen, Michael
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[6] Impact of Sotorasib and Adagrasib in KRAS G12C-Mutated NSCLC
Patel, Sandip P.
ONCOLOGY-NEW YORK, 2023, 37 (12): : 479 - 479
[7] Durability of Clinical Benefit and Biomarkers in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Sotorasib, a KRAS(G12C) Inhibitor
Hong, D. S.
Bang, Y. -J.
Barlesi, F.
Durm, G.
Falchook, G.
Govindan, R.
Dy, G.
Park, K.
Strickler, J.
Burns, T.
Kim, J.
Ang, A.
Lipford, J. R.
Ngarmchamnanrith, G.
Anderson, A.
Li, B. T.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S28 - S29
[8] Sotorasib in KRAS G12C-mutated non-small cell lung carcinoma
Lorenz, Judith
PNEUMOLOGIE, 2023, 77 (11): : 846 - 846
[9] Adagrasib (MRTX849) in patients with advanced/metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC): Preliminary analysis of mutation allele frequency
Janne, P. A.
Spira, A.
Riely, G. J.
Gadgeel, S.
Heist, R.
Ou, S-H. I.
Johnson, M. L.
Sabari, J.
Velastegui, K.
Christensen, J. G.
Yang, W.
Anderes, K.
Chao, R.
Paweletz, C.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S41 - S42
[10] Biomarker subgroup analyses of CodeBreaK 200, a phase 3 trial of sotorasib versus (vs) docetaxel in patients (pts) with pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC)
Skoulidis, Ferdinandos
De langen, Adrianus
Paz-Ares, Luis G.
Mountzios, Giannis Socrates
Curioni-Fontecedro, Alessandra
Couraud, Sebastien
Janssens, Annelies
Rocco, Danilo
Ohashi, Kadoaki
Vincent, Mark David
Kang, Jin-Hyoung
Schvartsman, Gustavo
Lindsay, Colin R.
O'Byrne, Kenneth John
Dziadziuszko, Rafal
Andersen, Jon A. Lykkegaard
Hindoyan, Antreas
Wilmanski, Tomasz
Wang, Yang
Schuler, Martin H.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 4 5 →